{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:18:15Z","timestamp":1780960695788,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Paratek"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40121-024-01057-3","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T17:01:44Z","timestamp":1729962104000},"page":"2637-2648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intravenous Versus Oral Omadacycline or Linezolid for Acute Bacterial Skin and Skin Infections: A post hoc Analysis of the OASIS Trials"],"prefix":"10.1007","volume":"13","author":[{"given":"George D.","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Yashayev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya","family":"Chitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Amodio-Groton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2908-2612","authenticated-orcid":false,"given":"Kelly","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"issue":"2","key":"1057_CR1","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1093\/cid\/ciu296","volume":"59","author":"DL Stevens","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-52.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1057_CR2","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1128\/AAC.01066-13","volume":"58","author":"MP Draper","year":"2014","unstructured":"Draper MP, Weir S, Macone A, et al. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother. 2014;58(3):1279\u201383.","journal-title":"Antimicrob Agents Chemother"},{"key":"1057_CR3","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2147\/IDR.S171352","volume":"12","author":"RM Burgos","year":"2019","unstructured":"Burgos RM, Rodvold KA. Omadacycline: a novel aminomethylcycline. Infect Drug Resist. 2019;12:1895\u2013915.","journal-title":"Infect Drug Resist"},{"issue":"3","key":"1057_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-020-01257-4","volume":"80","author":"GG Zhanel","year":"2020","unstructured":"Zhanel GG, Esquivel J, Zelenitsky S, et al. Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent. Drugs. 2020;80(3):285\u2013313.","journal-title":"Drugs"},{"issue":"2","key":"1057_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/ph12020063","volume":"12","author":"F Dur\u00e3es","year":"2019","unstructured":"Dur\u00e3es F, Sousa E. Omadacycline: a newly approved antibacterial from the class of tetracyclines. Pharmaceuticals (Basel). 2019;12(2):63.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1057_CR6","unstructured":"United States Food and Drug Administration. Zyvox (linezolid). Package insert. 2001. http:\/\/www.zyvox.com\/pdfs\/zyvox_full_prescribe_012001.pdf. Accessed 19 Jun 2024."},{"issue":"4","key":"1057_CR7","first-page":"663","volume":"65","author":"PW Ament","year":"2002","unstructured":"Ament PW, Jamshed N, Horne JP. Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections. Am Fam Physician. 2002;65(4):663\u201370.","journal-title":"Am Fam Physician"},{"issue":"11","key":"1057_CR8","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/phar.2625","volume":"41","author":"MR Bidell","year":"2021","unstructured":"Bidell MR, Lodise TP. Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline. Pharmacotherapy. 2021;41(11):915\u201331.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"1057_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1089\/sur.2020.436","volume":"22","author":"TM Duane","year":"2021","unstructured":"Duane TM, Huston JM, Collom M, et al. Surgical infection society 2020 updated guidelines on the management of complicated skin and soft tissue infections. Surg Infect (Larchmt). 2021;22(4):383\u201399.","journal-title":"Surg Infect (Larchmt)"},{"issue":"2","key":"1057_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.diagmicrobio.2014.02.011","volume":"79","author":"BA Lipsky","year":"2014","unstructured":"Lipsky BA, Napolitano LM, Moran GJ, Vo L, Nicholson S, Kim M. Inappropriate initial antibiotic treatment for complicated skin and soft tissue infections in hospitalized patients: incidence and associated factors. Diagn Microbiol Infect Dis. 2014;79(2):273\u20139.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"1057_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.diagmicrobio.2014.02.013","volume":"79","author":"BA Lipsky","year":"2014","unstructured":"Lipsky BA, Napolitano LM, Moran GJ, et al. Economic outcomes of inappropriate initial antibiotic treatment for complicated skin and soft tissue infections: a multicenter prospective observational study. Diagn Microbiol Infect Dis. 2014;79(2):266\u201372.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"1057_CR12","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3122\/jabfm.2013.05.120247","volume":"26","author":"MJ Labreche","year":"2013","unstructured":"Labreche MJ, Lee GC, Attridge RT, et al. Treatment failure and costs in patients with methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections: a South Texas Ambulatory Research Network (STARNet) study. J Am Board Fam Med. 2013;26(5):508\u201317.","journal-title":"J Am Board Fam Med"},{"issue":"3","key":"1057_CR13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1089\/sur.2012.103","volume":"14","author":"A Berger","year":"2013","unstructured":"Berger A, Oster G, Edelsberg J, Huang X, Weber DJ. Initial treatment failure in patients with complicated skin and skin structure infections. Surg Infect (Larchmt). 2013;14(3):304\u201312.","journal-title":"Surg Infect (Larchmt)"},{"issue":"5","key":"1057_CR14","first-page":"143","volume":"4","author":"A Pulido-Cejudo","year":"2017","unstructured":"Pulido-Cejudo A, Guzm\u00e1n-Gutierrez M, Jalife-Monta\u00f1o A, et al. Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure. Ther Adv Infect Dis. 2017;4(5):143\u201361.","journal-title":"Ther Adv Infect Dis"},{"issue":"6","key":"1057_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1086\/511872","volume":"44","author":"JJ Ruhe","year":"2007","unstructured":"Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis. 2007;44(6):777\u201384.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1057_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/jamadermatol.2016.3816","volume":"153","author":"QY Weng","year":"2017","unstructured":"Weng QY, Raff AB, Cohen JM, et al. Costs and consequences associated with misdiagnosed lower extremity cellulitis. JAMA Dermatol. 2017;153(2):141\u20136.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1057_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s15010-019-01347-w","volume":"48","author":"K Yadav","year":"2020","unstructured":"Yadav K, Nath A, Suh KN, Sikora L, Eagles D. Treatment failure definitions for non-purulent skin and soft tissue infections: a systematic review. Infection. 2020;48(1):75\u201383.","journal-title":"Infection"},{"issue":"2","key":"1057_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/QCO.0000000000000822","volume":"35","author":"A Russo","year":"2022","unstructured":"Russo A, Vena A, Bassetti M. Antibiotic treatment of acute bacterial skin and skin structure infections. Curr Opin Infect Dis. 2022;35(2):120\u20137.","journal-title":"Curr Opin Infect Dis"},{"issue":"10","key":"1057_CR19","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","volume":"19","author":"W O'Riordan","year":"2019","unstructured":"O\u2019Riordan W, Cardenas C, Shin E, et al. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis. 2019;19(10):1080\u201390.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"1057_CR20","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1056\/NEJMoa1800170","volume":"380","author":"W O'Riordan","year":"2019","unstructured":"O\u2019Riordan W, Green S, Overcash JS, et al. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med. 2019;380(6):528\u201338.","journal-title":"N Engl J Med"},{"key":"1057_CR21","unstructured":"United States Food and Drug Administration. Acute bacterial skin and skin structure infections: developing drugs for treatment. 2013. https:\/\/www.fda.gov\/media\/71052\/download. Accessed 19 Jun 2024"},{"issue":"2","key":"1057_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/sim.4780040211","volume":"4","author":"O Miettinen","year":"1985","unstructured":"Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4(2):213\u201326.","journal-title":"Stat Med"},{"issue":"Suppl 1","key":"1057_CR23","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1093\/cid\/ciz398","volume":"69","author":"S Opal","year":"2019","unstructured":"Opal S, File TM, van der Poll T, Tzanis E, Chitra S, McGovern PC. An integrated safety summary of omadacycline, a novel aminomethylcycline antibiotic. Clin Infect Dis. 2019;69(Suppl 1):S40\u20137.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1057_CR24","doi-asserted-by":"publisher","first-page":"ofab459","DOI":"10.1093\/ofid\/ofab459","volume":"8","author":"S Chitra","year":"2021","unstructured":"Chitra S, Hinahara J, Goss TF, Gunter K, LaPensee K. Health-related quality of life as measured by the 36-item short form survey among adults with acute bacterial skin and skin structure infections who received either omadacycline or linezolid in a phase 3 double-blind, double-dummy clinical trial. Open Forum Infect Dis. 2021;8(10):ofab459.","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"1057_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049733","volume":"11","author":"M Dimitrova","year":"2021","unstructured":"Dimitrova M, Gilchrist M, Seaton RA. Outpatient parenteral antimicrobial therapy (OPAT) versus inpatient care in the UK: a health economic assessment for six key diagnoses. BMJ Open. 2021;11(9): e049733.","journal-title":"BMJ Open"},{"issue":"6","key":"1057_CR26","doi-asserted-by":"publisher","first-page":"R184","DOI":"10.1186\/cc2388","volume":"7","author":"AR van Zanten","year":"2003","unstructured":"van Zanten AR, Engelfriet PM, van Dillen K, van Veen M, Nuijten MJ, Polderman KH. Importance of nondrug costs of intravenous antibiotic therapy. Crit Care. 2003;7(6):R184\u201390.","journal-title":"Crit Care"},{"issue":"5","key":"1057_CR27","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1093\/jac\/dkaa558","volume":"76","author":"MP Pai","year":"2021","unstructured":"Pai MP, Wilcox MH, Chitra S, McGovern PC. Safety and efficacy of omadacycline by BMI categories and diabetes history in two phase III randomized studies of patients with acute bacterial skin and skin structure infections. J Antimicrob Chemother. 2021;76(5):1315\u201322.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"1057_CR28","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/jac\/dkac030","volume":"77","author":"G Sakoulas","year":"2022","unstructured":"Sakoulas G. Linezolid versus omadacycline in diabetic soft tissue infections: a signal of different adjunctive immunological properties? J Antimicrob Chemother. 2022;77(6):1503\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"1057_CR29","first-page":"952","volume":"29","author":"TP Lodise","year":"2023","unstructured":"Lodise TP, Gunter K, Mu F, et al. Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections. J Manag Care Spec Pharm. 2023;29(8):952\u201364.","journal-title":"J Manag Care Spec Pharm"},{"issue":"Suppl 1","key":"1057_CR30","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/cid\/ciz396","volume":"69","author":"FM Abrahamian","year":"2019","unstructured":"Abrahamian FM, Sakoulas G, Tzanis E, et al. Omadacycline for acute bacterial skin and skin structure infections. Clin Infect Dis. 2019;69(Suppl 1):S23-s32.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1057_CR31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40121-021-00587-4","volume":"11","author":"GJ Moran","year":"2022","unstructured":"Moran GJ, Chitra S, McGovern PC. Efficacy and safety of omadacycline versus linezolid in acute bacterial skin and skin structure infections in persons who inject drugs. Infect Dis Ther. 2022;11(1):517\u201331.","journal-title":"Infect Dis Ther"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01057-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-01057-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01057-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T15:09:13Z","timestamp":1732201753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-01057-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1057"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-01057-3","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"26 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nathan Warren and Surya Chitra are Consultants for Paratek Pharmaceuticals, Inc. George D. Rodriguez has received travel support to present a poster version of this manuscript. Roman Yashayev declares that he has no competing interests. Maria Amodio-Groton and Kelly Wright are employees and shareholders of Paratek Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The OASIS-1 (ClinicalTrials.gov identifier NCT02378480) and OASIS-2 (ClinicalTrials.gov identifier NCT02877927) trials included in this post hoc analysis were conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki of 1964, and its later amendments. They were approved by the Institutional Review Board (IRB) or Ethics Committee (EC) at each participating site (Supplementary Table S3); the IRB\/EC at each participating site approved the protocol and amendments. Each patient provided written informed consent prior to study participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}